Research confirms benefits of side-actuated nasal spray

Published: 8-Feb-2010
Ingredients Drug Delivery Research & Development Pharmaceutical

Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.

Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.

The side-actuated nasal spray consists of a standard actuator coupled with a customisable shell and cap.

The research, carried out in the UK last November involving 10 regular nasal spray users, as well as six doctors (GPs and ENT specialists), showed that the side-actuated delivery device has the three advantages mentioned above.

Patients also thought a slightly longer nozzle would improve the placement of the device in the nostril when the device is actuated, and Valois will further investigate this.

The company says new user research will be carried out in the US in the coming months to confirm the results of the current study.




See more

You may also like

Manufacturing

Redefining QP training for today’s professionals

Read more
How NSF is making specialist learning more flexible and accessible

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Polpharma Biologics announces US launch of Tyruko, the first FDA-approved natalizumab biosimilar for MS Tyruko is now available to US patients with multiple sclerosis and Crohn’s disease, expanding access to a more affordable biologic option
  3. UK Invests £9.9m to turn recycled nuclear material into lead-212 cancer therapies A new UK-wide programme will use recycled nuclear fuel to create sustainable lead-212 targeted alpha therapies, aiming to deliver next-generation precision cancer treatments for hard-to-treat tumours
  4. American Cancer Society expands ACS ACTS programme to boost equity in cancer clinical trials nationwide Leveraging trained specialists and AI-powered trial matching, the ACS ACTS programme helps patients, caregivers and providers navigate clinical trial options while addressing barriers to participation
  5. DBV Technologies announces last patient visit completed in Phase III peanut allergy trial in children The Phase III VITESSE clinical trial of the VIASKIN Peanut patch in peanut allergic children aged 4-7 years remains on track for topline data in Q4 of this year

You may also like

Manufacturing

Redefining QP training for today’s professionals

How NSF is making specialist learning more flexible and accessible
Manufacturing

NSF’s QP training program combines technical skill with personalised guidance

A mentoring-led approach supporting delegates through every stage of the QP journey
Research & Development

Bayer expands global partnership with TetraScience to accelerate AI-driven scientific data management

Bayer is scaling TetraScience’s Scientific Data Foundry across its pharma and crop science R&D teams to unify and harmonise laboratory and CRO data. The expansion aims to streamline regulatory workflows and enable faster, AI-ready analysis across global programmes
Sustainability

Solvent recyclers improve HPLC system sustainability

A leading pharmaceutical company has purchased 17 SPR-200 solvent recycler units from Biotech Fluidics improving sustainable use of solvents by HPLC systems in their analytical laboratories
Research & Development

ChristianaCare launches organoid core to personalise cancer treatment in Delaware

The new facility at the Helen F. Graham Cancer Center grows patient-derived mini-tumours to test therapies, helping doctors tailor cancer treatments and accelerate translational research in a community setting
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Drug Delivery

Science based targets initiative confirms CO2e reduction targets

Targets align with the Paris Agreement to limit global warming to 1.5 °C. Reduction of Scope 1 and 2 emissions by 52% by 2030 and reduction of the intensity of selected Scope 3 emissions by 64% by 2034
Subscribe now